Ablation..........................................................................................120
ABO................................................................................................135
Active surveillance..........................................................................107
Anesthesia..........................................................................................1
Angiogenesis....................................................................................18
Autologous stem-cell transplantation..............................................143
BCG................................................................................................124
Benign prostatic hyperplasia...........................................................113
Benign renal tumor........................................................................158
Biopsy.................................................................................................1
Bladder.......................................................................6,18,89,124,127
Bladder neoplasms...........................................................................18
Bladder tumor..................................................................................51
Blood group...................................................................................135
Cancer-specific survival.....................................................................99
Cardiovascular disease risk................................................................59
Checkpoint blockers.........................................................................67
Complications..................................................................................46
Cost-benefit....................................................................................117
Cryotherapy....................................................................................120
Cystectomy......................................................................................89
Defensive surgery.............................................................................51
Detrusor muscle................................................................................51
Diagnostic marker............................................................................30
Early bladder chemotherapy instillation............................................24
Efficacy...........................................................................................143
Exenteration.....................................................................................89
Female..............................................................................................89
FNCLCC grading system...................................................................93
Framingham risk score......................................................................59
Genitourinary sarcomas....................................................................93
Germ cell tumors............................................................................143
Hepatititis.......................................................................................124
High-dose chemotherapy...............................................................143
Immunotherapy................................................................................67
Intravesical BCG...............................................................................24
Intravesical chemotherapy................................................................24
Invasion..............................................................................................6
lamina propria....................................................................................6
Laparoscopic surgery......................................................................154
Laparoscopy...................................................................................158
Lower urinary tract symptoms........................................................107
Lymphocyte-to-monocyte ratio......................................................138
Medical students..............................................................................10
MicroRNA-21....................................................................................30
Molecular markers.....................................................................18,127
MRI..................................................................................................55
mRNA expression...........................................................................149
Multilocular cystic renal cell carcinoma.............................................55
Nanomedicine..................................................................................34
Nanotechnology...............................................................................34
Nephrectomy..............................................................................59,99
Neutrophil-lymphocyte ratio............................................................40
Neutrophil-to-lymphocyte ratio......................................................138
Neutrophilto-monocyte ratio..........................................................138
Non-muscle invasive bladder tumor........................................24,30,40
Oncologic outcomes.........................................................................59
Outcomes.........................................................................................14
Overall survival.................................................................................93
Pain....................................................................................................1
Paratesticular sarcomas.....................................................................93
Partial nephrectomy................................................................154,158
Platelet-to-lymphocyte ratio............................................................138
Prognosis.....................................................................................18,99
Progression.......................................................................................40
Prostate..............................................................................................1
Prostate biopsy..........................................................................46,138
Prostate cancer..................................................14,34,67,107,113,138
PSMA...............................................................................................34
Radical nephrectomy......................................................................158
Radiofrequency ablation.................................................................120
Radiology.........................................................................................80
Radionuclide imaging.......................................................................80
RCC................................................................................................149
Recurrence, prognosis......................................................................40
Renal cell carcinoma..........................................................55,59,73,99
Renal leiomyoma............................................................................158
Renal tumor....................................................................................154
Resistance mechanisms.....................................................................73
Rhesus............................................................................................135
Risk factors.......................................................................................46
Robotic surgery.......................................................................117,154
Robotic-assisted laparoscopic prostatectomy....................................14
Small renal mass.............................................................................120
Smear ..............................................................................................89
Superficial...........................................................................................6
Survival.............................................................................................67
Survival analysis................................................................................99
Tamsulosin......................................................................................107
Testicular cancer........................................................................10,135
Testicular self-examination................................................................10
Theranostic concepts........................................................................34
TLR.................................................................................................149
Tumor markers.................................................................................18
TUR-BT.............................................................................................51
Tyrosine kinase inhibitors .................................................................73
Urinary biomarkers.........................................................................127
Urological neoplasms........................................................................80
Urology..........................................................................................117
Vaccine.............................................................................................67
Vitamin D.......................................................................................113
